{"id":780,"date":"2024-10-16T10:38:18","date_gmt":"2024-10-16T10:38:18","guid":{"rendered":"http:\/\/eurosoi.org\/?p=780"},"modified":"2024-10-16T10:38:18","modified_gmt":"2024-10-16T10:38:18","slug":"this-scholarly-study-confirmed-that-only-patients-with-wild-type-reap-the-benefits-of-panitumumab-containing-chemotherapy-228","status":"publish","type":"post","link":"https:\/\/eurosoi.org\/?p=780","title":{"rendered":"\ufeffThis scholarly study confirmed that only patients with wild-type reap the benefits of panitumumab-containing chemotherapy [228]"},"content":{"rendered":"<p>\ufeffThis scholarly study confirmed that only patients with wild-type reap the benefits of panitumumab-containing chemotherapy [228]. the elements that determine 5-FU response. Initiatives are getting designed to identify mutations or genetic polymorphisms in sufferers who have are resistant or private to 5-FU. As continues to be mentioned above, among the targets of 5-FU AVN-944 is the enzyme thymidylate synthase. The therapeutic response to 5-FU has been shown to be associated with the extent of inhibition of thymidylate synthase activity [32]. The extent of inhibition of TS activity depend in part on the levels of thymidylate synthase and 5,10-methylene-THF. The amount of 5,10-methyleneTHF in cells is regulated by methylenetetrahydrofolate reductase (MTHFR). MTHFR reduces the cofactor to 5-methyltetrahydrofolate [33] (Scheme 2). Given the importance of the level of TS and the activity of MTHFR to thymidylate synthase inhibition, candidate genes that would influence response to 5-FU would be the genes that encode these two enzymes, (for TS) and (for MTHFR). A common variant of is 677C T (A222V). This polymorphism has been associated with reduced MTHFR activity [34]. In a number of studies [35,36], the presence of the polymorphism, especially in a homozygous fashion [37,38], has been correlated with response to 5-FU-based treatment. In other studies, no relationship has AVN-944 been found between the polymorphism and response to different 5-FU based chemotherapeutic regimens [39,40]. The conflicting results on the impact of polymorphism on <a href=\"http:\/\/www.play-hookey.com\/dc_theory\/components_inductors.html\">MIS<\/a> response to 5-FU can explain at least in part why screening AVN-944 for variant prior to 5-FU-based treatment has not been adopted. polymorphisms have also been shown to influence sensitivity to 5-FU-based chemotherapy. The promoter enhancer region of the gene contains a tandemly repeated sequence [41]. The number of repeats of this sequence influences the translational efficiency of the mRNA [42,43]. The most common alleles have a double repeat (allele [46,47,48,49]. Not all patients, however, that are have high TS expression [46] or <a href=\"https:\/\/www.adooq.com\/avn-944.html\">AVN-944<\/a> are unresponsive to 5FU treatment [50]. A G C variant has been identified in the 2nd repeat of the allele [51]. This transversion reduces the transcriptional activity of the promoter. Patients that homozygous but have the G C variant (*3C) have lower TS expression and respond better to 5-FU than patients with the allele containing AVN-944 the G (3G) [52]. The use of thymidylate synthase expression in resected tumors to predict 5-FU response has been explored. Patients that have high expression levels in their resected tumors respond poorly to 5-FU and leucovorin [53,54,55,56] and to a combination of 5-FU\/LV and oxaliplatin [57]. On the other hand, not all patients that have low expression respond to 5-FU-based therapy [54]. Thus, TS expression may actually be more of a predictor of 5-FU resistance, rather than response. copy number gains may also be predictive of 5-FU resistance. Patients that have been previously treated with 5-FU based chemotherapy and had amplification of their gene had shorter survival times than patients that did not have gene amplification [58,59]. The efficacy of 5-FU-based chemotherapy is dependent in part on the 5-FU plasma levels achieved in a patient [60,61,62]. Given that 80% of administered 5-FU is degraded [63] and only 1C3% of the drug is actually anabolized [64], the extent of 5-FU catabolism largely determines 5-FU levels. The rate-limiting step in 5-FU catabolism is catalyzed by the enzyme dihydropyrimidine dehydrogenase (DPD) [64]. Low DPD expression has been observed among patients who responded to 5-FU treatment [65,66]. However, no genetic polymorphism has been found to be predictive of DPD deficiency [67]. Nonetheless, some DPYD SNPs have been proposed for clinical use to avoid severe side effects from 5-FU [68] (see below). One of the mechanisms of action of 5-FU involves the DNA repair pathway. It is conceivable, therefore, that response to 5-FU can be affected by the status of the DNA repair machinery. It has been found that 12C28% of colorectal cancers have.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ufeffThis scholarly study confirmed that only patients with wild-type reap the benefits of panitumumab-containing chemotherapy [228]. the elements that determine 5-FU response. Initiatives are getting designed to identify mutations or genetic polymorphisms in sufferers who have are resistant or private to 5-FU. As continues to be mentioned above, among the <a href=\"https:\/\/eurosoi.org\/?p=780\" class=\"btn btn-link continue-link\">Continue Reading<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17],"tags":[],"class_list":["post-780","post","type-post","status-publish","format-standard","hentry","category-low-density-lipoprotein-receptors"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\ufeffThis scholarly study confirmed that only patients with wild-type reap the benefits of panitumumab-containing chemotherapy [228] - JAK2 inhibitor against human prostate cancer cells<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/eurosoi.org\/?p=780\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeffThis scholarly study confirmed that only patients with wild-type reap the benefits of panitumumab-containing chemotherapy [228] - JAK2 inhibitor against human prostate cancer cells\" \/>\n<meta property=\"og:description\" content=\"\ufeffThis scholarly study confirmed that only patients with wild-type reap the benefits of panitumumab-containing chemotherapy [228]. the elements that determine 5-FU response. Initiatives are getting designed to identify mutations or genetic polymorphisms in sufferers who have are resistant or private to 5-FU. As continues to be mentioned above, among the Continue Reading\" \/>\n<meta property=\"og:url\" content=\"https:\/\/eurosoi.org\/?p=780\" \/>\n<meta property=\"og:site_name\" content=\"JAK2 inhibitor against human prostate cancer cells\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-16T10:38:18+00:00\" \/>\n<meta name=\"author\" content=\"info\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"info\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=780#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=780\"},\"author\":{\"name\":\"info\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\"},\"headline\":\"\ufeffThis scholarly study confirmed that only patients with wild-type reap the benefits of panitumumab-containing chemotherapy [228]\",\"datePublished\":\"2024-10-16T10:38:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=780\"},\"wordCount\":631,\"articleSection\":[\"Low-density Lipoprotein Receptors\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=780\",\"url\":\"https:\\\/\\\/eurosoi.org\\\/?p=780\",\"name\":\"\ufeffThis scholarly study confirmed that only patients with wild-type reap the benefits of panitumumab-containing chemotherapy [228] - JAK2 inhibitor against human prostate cancer cells\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#website\"},\"datePublished\":\"2024-10-16T10:38:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=780#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/eurosoi.org\\\/?p=780\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=780#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/eurosoi.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\ufeffThis scholarly study confirmed that only patients with wild-type reap the benefits of panitumumab-containing chemotherapy [228]\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#website\",\"url\":\"https:\\\/\\\/eurosoi.org\\\/\",\"name\":\"JAK2 inhibitor against human prostate cancer cells\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/eurosoi.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\",\"name\":\"info\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"caption\":\"info\"},\"sameAs\":[\"http:\\\/\\\/eurosoi.org\"],\"url\":\"https:\\\/\\\/eurosoi.org\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\ufeffThis scholarly study confirmed that only patients with wild-type reap the benefits of panitumumab-containing chemotherapy [228] - JAK2 inhibitor against human prostate cancer cells","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/eurosoi.org\/?p=780","og_locale":"en_US","og_type":"article","og_title":"\ufeffThis scholarly study confirmed that only patients with wild-type reap the benefits of panitumumab-containing chemotherapy [228] - JAK2 inhibitor against human prostate cancer cells","og_description":"\ufeffThis scholarly study confirmed that only patients with wild-type reap the benefits of panitumumab-containing chemotherapy [228]. the elements that determine 5-FU response. Initiatives are getting designed to identify mutations or genetic polymorphisms in sufferers who have are resistant or private to 5-FU. As continues to be mentioned above, among the Continue Reading","og_url":"https:\/\/eurosoi.org\/?p=780","og_site_name":"JAK2 inhibitor against human prostate cancer cells","article_published_time":"2024-10-16T10:38:18+00:00","author":"info","twitter_card":"summary_large_image","twitter_misc":{"Written by":"info","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/eurosoi.org\/?p=780#article","isPartOf":{"@id":"https:\/\/eurosoi.org\/?p=780"},"author":{"name":"info","@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd"},"headline":"\ufeffThis scholarly study confirmed that only patients with wild-type reap the benefits of panitumumab-containing chemotherapy [228]","datePublished":"2024-10-16T10:38:18+00:00","mainEntityOfPage":{"@id":"https:\/\/eurosoi.org\/?p=780"},"wordCount":631,"articleSection":["Low-density Lipoprotein Receptors"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/eurosoi.org\/?p=780","url":"https:\/\/eurosoi.org\/?p=780","name":"\ufeffThis scholarly study confirmed that only patients with wild-type reap the benefits of panitumumab-containing chemotherapy [228] - JAK2 inhibitor against human prostate cancer cells","isPartOf":{"@id":"https:\/\/eurosoi.org\/#website"},"datePublished":"2024-10-16T10:38:18+00:00","author":{"@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd"},"breadcrumb":{"@id":"https:\/\/eurosoi.org\/?p=780#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/eurosoi.org\/?p=780"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/eurosoi.org\/?p=780#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/eurosoi.org\/"},{"@type":"ListItem","position":2,"name":"\ufeffThis scholarly study confirmed that only patients with wild-type reap the benefits of panitumumab-containing chemotherapy [228]"}]},{"@type":"WebSite","@id":"https:\/\/eurosoi.org\/#website","url":"https:\/\/eurosoi.org\/","name":"JAK2 inhibitor against human prostate cancer cells","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/eurosoi.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd","name":"info","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","caption":"info"},"sameAs":["http:\/\/eurosoi.org"],"url":"https:\/\/eurosoi.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=780"}],"version-history":[{"count":1,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/780\/revisions"}],"predecessor-version":[{"id":781,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/780\/revisions\/781"}],"wp:attachment":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}